Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy

期刊论文
出版模式：

开放获取
发表日期：

2024年12月2日

查看全文

Toshiyuki Tanaka,
Tomoki Motegi,
Misaki Mori,
Nanami Sumikawa,
Kaito Maeda,
Yasumasa Iimori,
Hideo Akiyoshi

摘要

Objectives

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the expression of target genes. Therefore, the efficacy of the targeted therapies for canine HCC remains unclear.

Data description

Liver specimens were obtained from 11 dogs with HCC and four dogs without HCC. We performed RNA seq using the mRNA extracted from the specimens. Differentially expressed genes (DEGs) between canine HCC and normal liver were explored based on previously reported molecular-targeted agents for human tumours. PARP3, DNMT1, FGF19, FGF23, and RET DEGs were upregulated, whereas KIT, FGFR2, and FGF21 DEGs were downregulated.